1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2015

Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2015" provides an overview of Severe Combined Immune Deficiency (SCID) clinical trials scenario. This report provides top line data relating to the clinical trials on Severe Combined Immune Deficiency (SCID). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Europe 8
Top Countries Contributing to Clinical Trials in North America 9
Top Countries Contributing to Clinical Trials in Middle East and Africa 10
Clinical Trials by G7 Countries: Proportion of Severe Combined Immune Deficiency (SCID) to Genetic Disorders Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by Phase 14
In Progress Trials by Phase 15
Clinical Trials by Trial Status 16
Clinical Trials by End Point Status 17
Subjects Recruited Over a Period of Time 18
Clinical Trials by Sponsor Type 19
Prominent Sponsors 20
Top Companies Participating in Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials 21
Prominent Drugs 22
Clinical Trial Profile Snapshots 23
Appendix 47
Abbreviations 47
Definitions 47
Research Methodology 48
Secondary Research 48
About GlobalData 49
Contact Us 49
Disclaimer 49
Source 50

List of Tables
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials by Region, 2015* 5
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 7
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Europe, Top Countries, 2015* 8
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, North America, Top Countries, 2015* 9
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 10
Proportion of Severe Combined Immune Deficiency (SCID) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 11
Severe Combined Immune Deficiency (SCID) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 12
Severe Combined Immune Deficiency (SCID) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 13
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials by Phase, 2015* 14
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 15
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 16
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 17
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 18
Severe Combined Immune Deficiency (SCID) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 19
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 20
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 21
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 22

List of Figures
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials by Region (%), 2015* 5
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 6
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 7
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Europe, Top Countries (%), 2015* 8
Proportion of Severe Combined Immune Deficiency (SCID) to Genetic Disorders Clinical Trials, G7 Countries (%), 2015* 11
Severe Combined Immune Deficiency (SCID) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 12
Severe Combined Immune Deficiency (SCID) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 13
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 14
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 15
Severe Combined Immune Deficiency (SCID) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 16
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 17
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 18
Severe Combined Immune Deficiency (SCID) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 19
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 20
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 21
Severe Combined Immune Deficiency (SCID) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 22
GlobalData Methodology 48

Companies Mentioned
Sigma-Tau S.p.A.
Parexel International Corporation
Orphan Technologies Ltd
Miltenyi Biotec GmbH
GlaxoSmithKline Plc
Chimerix, Inc.
Bio Products Laboratory Limited
Alexion Pharmaceuticals, Inc.
acromion GmbH

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.